Miragen Therapeutics (NASDAQ:MGEN) posted its quarterly earnings results on Wednesday, March 14th. The medical research company reported ($0.29) EPS for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.04, Bloomberg Earnings reports. Miragen Therapeutics had a negative return on equity of 63.57% and a negative net margin of 662.30%. The business had revenue of $1.19 million during the quarter, compared to analysts’ expectations of $1.22 million.
Shares of NASDAQ MGEN traded down $0.37 during midday trading on Friday, reaching $6.50. 219,209 shares of the company were exchanged, compared to its average volume of 380,594. The stock has a market cap of $207.28, a PE ratio of -4.71 and a beta of 1.33. Miragen Therapeutics has a one year low of $5.01 and a one year high of $15.91. The company has a debt-to-equity ratio of 0.26, a quick ratio of 13.33 and a current ratio of 13.33.
In other Miragen Therapeutics news, insider Adam Scott Levy acquired 9,090 shares of Miragen Therapeutics stock in a transaction that occurred on Tuesday, February 13th. The shares were bought at an average price of $5.50 per share, with a total value of $49,995.00. Following the completion of the purchase, the insider now directly owns 10,540 shares in the company, valued at approximately $57,970. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Bruce Booth acquired 545,454 shares of Miragen Therapeutics stock in a transaction that occurred on Tuesday, February 13th. The stock was acquired at an average cost of $5.50 per share, for a total transaction of $2,999,997.00. The disclosure for this purchase can be found here. Insiders own 44.40% of the company’s stock.
A number of research firms have recently weighed in on MGEN. B. Riley initiated coverage on shares of Miragen Therapeutics in a research report on Friday, January 5th. They issued a “buy” rating and a $15.50 price target for the company. Deutsche Bank initiated coverage on shares of Miragen Therapeutics in a research report on Thursday, March 22nd. They set a “buy” rating and a $15.00 price objective for the company. Chardan Capital restated a “buy” rating on shares of Miragen Therapeutics in a research report on Tuesday, January 16th. Zacks Investment Research upgraded shares of Miragen Therapeutics from a “hold” rating to a “buy” rating and set a $10.00 price objective for the company in a research report on Tuesday, January 9th. Finally, Cann restated a “buy” rating and set a $13.00 price objective on shares of Miragen Therapeutics in a research report on Friday, February 2nd. One analyst has rated the stock with a sell rating, one has issued a hold rating and nine have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $16.31.
ILLEGAL ACTIVITY WARNING: “Miragen Therapeutics (MGEN) Announces Earnings Results” was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2018/04/07/miragen-therapeutics-mgen-posts-earnings-results-beats-expectations-by-0-04-eps.html.
Miragen Therapeutics Company Profile
Signal Genetics, Inc is a commercial stage, molecular genetic diagnostic company. The Company is focused on providing diagnostic services that help physicians to make decisions concerning the care of cancer patients. The Company’s diagnostic service is the Myeloma Prognostic Risk Signature (MyPRS) test.
Receive News & Ratings for Miragen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Miragen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.